X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

ICYMI: PhRMA COO Lori Reilly speaks about the health care agenda for the next Congress

By Lori Reilly  |    December 9, 2022
With a divided Congress, bipartisan action will be necessary to move the needle on health care policy. On December 7, 2022, PhRMA sponsored the Axios event, “The Post-Midterm Health Care Agenda,”...   Read More

What they are saying: PASTEUR Act can help fight antimicrobial resistance

By Andrew Powaleny  |    November 30, 2022
Antimicrobial resistance (AMR) is a growing health crisis resulting in nearly 50,000 U.S. deaths each year and 1.27 million globally on an annual basis – higher than HIV/AIDS and malaria. To slow and...   Read More

ICYMI: Increase in drug-resistant superbugs during COVID-19 highlights need for policy reforms to address antimicrobial resistance

By Andrew Powaleny  |    July 14, 2022
A new report released by the U.S. Centers for Disease Control and Prevention (CDC) shows the number of antimicrobial-resistant (AMR) infections rose dramatically during the first year of the COVID-19...   Read More

ICYMI: Antimicrobial resistance spotlighted as growing public health threat

By Andrew Powaleny  |    July 6, 2022
On June 28, PhRMA Chief Operating Officer Lori Reilly joined Executive Director of CARB-X, Kevin Outterson, Esq., and Interim Secretariat Lead of the Global Antimicrobial Resistance (AMR) R&D Hub,...   Read More

ICYMI: PhRMA CEO Stephen J. Ubl spotlights lessons learned during COVID-19

By Andrew Powaleny  |    May 13, 2022
This week, PhRMA sponsored The Washington Post’s event, Coronavirus: Lessons of the Pandemic, where PhRMA president and CEO Stephen J. Ubl shared crucial lessons learned from the pandemic on how to...   Read More

ICYMI: New resource catalogs biopharmaceutical industry lessons learned from COVID-19

By Gabby Migliara  |    April 28, 2022
Since the start of the pandemic, America’s biopharmaceutical companies have worked around the clock to research, develop and manufacture treatments and vaccines to fight COVID-19. We’ve made...   Read More

ICYMI: New report demonstrates growing global impact of antimicrobial resistance

By Jocelyn Ulrich  |    January 24, 2022
New research published in The Lancet shows for the first time the global impact of antimicrobial resistance (AMR), which poses an increasingly serious threat to human health around the world. The...   Read More

Preventing the next public health emergency: New evidence demonstrates need to address antimicrobial resistance

By Jocelyn Ulrich  |    November 18, 2021
COVID-19 is not the first pandemic caused by a novel strain of a virus affecting the upper respiratory tract. Over the past 100 years, pandemics have been caused by novel forms of influenza and other...   Read More

New PhRMA report shows nearly 90 medicines in development to fight drug-resistant infections, but future pipeline remains challenging

By Andrew Powaleny  |    April 29, 2021
The discovery and introduction of antibiotics in the 1940s transformed modern medicine and enabled tremendous progress in health care and life expectancy. Today, this progress is being threatened by...   Read More

ICYMI: Report provides actionable recommendations to strengthen America’s preparedness and future health crises response

By Jocelyn Ulrich  |    February 22, 2021
As America’s biopharmaceutical researchers continue working around the clock to fight COVID-19, leaders in the health care ecosystem have come together to provide recommendations to strengthen...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates